Success Metrics

Clinical Success Rate
80.6%

Based on 25 completed trials

Completion Rate
81%(25/31)
Active Trials
5(12%)
Results Posted
68%(17 trials)
Terminated
6(15%)

Phase Distribution

Ph phase_1
11
27%
Ph phase_4
4
10%
Ph early_phase_1
1
2%
Ph phase_2
16
39%
Ph not_applicable
4
10%
Ph phase_3
5
12%

Phase Distribution

12

Early Stage

16

Mid Stage

9

Late Stage

Phase Distribution41 total trials
Early Phase 1First-in-human
1(2.4%)
Phase 1Safety & dosage
11(26.8%)
Phase 2Efficacy & side effects
16(39.0%)
Phase 3Large-scale testing
5(12.2%)
Phase 4Post-market surveillance
4(9.8%)
N/ANon-phased studies
4(9.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.6%

25 of 31 finished

Non-Completion Rate

19.4%

6 ended early

Currently Active

5

trials recruiting

Total Trials

41

all time

Status Distribution
Active(6)
Completed(25)
Terminated(6)
Other(4)

Detailed Status

Completed25
Terminated6
Recruiting3
unknown3
Active, not recruiting2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
41
Active
5
Success Rate
80.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.4%)
Phase 111 (26.8%)
Phase 216 (39.0%)
Phase 35 (12.2%)
Phase 44 (9.8%)
N/A4 (9.8%)

Trials by Status

recruiting37%
suspended12%
terminated615%
completed2561%
not_yet_recruiting12%
active_not_recruiting25%
unknown37%

Recent Activity

Clinical Trials (41)

Showing 20 of 41 trialsScroll for more
NCT04038619Phase 1

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Recruiting
NCT02858310Phase 1

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed
NCT07426822Phase 2

Rash & Diarrhea Prophylaxis With Capivasertib

Not Yet Recruiting
NCT01391962Phase 2

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Completed
NCT02057133Phase 1

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Active Not Recruiting
NCT06865677Phase 2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Terminated
NCT05520723Phase 2

Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

Completed
NCT06892093Not Applicable

Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients

Recruiting
NCT03094052Phase 2

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Completed
NCT05677282Phase 4

Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct

Recruiting
NCT05252988Phase 2

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

Active Not Recruiting
NCT04225078Phase 1

A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants

Completed
NCT03030417Phase 1

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Completed
NCT02711891Early Phase 1

Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing

Completed
NCT04172597Phase 2

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Terminated
NCT04366713Phase 2

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Completed
NCT05252546Phase 1

Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

Completed
NCT04315116Phase 1

A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate

Completed
NCT03501498Not Applicable

Gut Transit Effect on Enterohepatic Circulation

Completed
NCT02400476Phase 2

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Completed

Drug Details

Intervention Type
OTHER
Total Trials
41